Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CIMAvax-EGF: Toward long-term survival of advanced NSCLC.
Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T. Saavedra D, et al. Among authors: viada c. Semin Oncol. 2018 Jan;45(1-2):34-40. doi: 10.1053/j.seminoncol.2018.04.009. Epub 2018 May 1. Semin Oncol. 2018. PMID: 30318082 Free article. Review.
Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule.
Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, Neninger E, Rodríguez PC, González Z, González A, Crombet T, Mazorra Z. Popa X, et al. Among authors: viada ce. Oncoimmunology. 2020 May 25;9(1):1762465. doi: 10.1080/2162402X.2020.1762465. Oncoimmunology. 2020. PMID: 32923124 Free PMC article.
Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. García B, et al. Among authors: viada c. Clin Cancer Res. 2008 Feb 1;14(3):840-6. doi: 10.1158/1078-0432.CCR-07-1050. Clin Cancer Res. 2008. PMID: 18245547 Clinical Trial.
A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC, Popa X, Martínez O, Mendoza S, Santiesteban E, Crespo T, Amador RM, Fleytas R, Acosta SC, Otero Y, Romero GN, de la Torre A, Cala M, Arzuaga L, Vello L, Reyes D, Futiel N, Sabates T, Catala M, Flores YI, Garcia B, Viada C, Lorenzo-Luaces P, Marrero MA, Alonso L, Parra J, Aguilera N, Pomares Y, Sierra P, Rodríguez G, Mazorra Z, Lage A, Crombet T, Neninger E. Rodriguez PC, et al. Among authors: viada c. Clin Cancer Res. 2016 Aug 1;22(15):3782-90. doi: 10.1158/1078-0432.CCR-15-0855. Epub 2016 Feb 29. Clin Cancer Res. 2016. PMID: 26927662 Clinical Trial.
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients.
Alfonso S, Valdés-Zayas A, Santiesteban ER, Flores YI, Areces F, Hernández M, Viada CE, Mendoza IC, Guerra PP, García E, Ortiz RA, de la Torre AV, Cepeda M, Pérez K, Chong E, Hernández AM, Toledo D, González Z, Mazorra Z, Crombet T, Pérez R, Vázquez AM, Macías AE. Alfonso S, et al. Among authors: viada ce. Clin Cancer Res. 2014 Jul 15;20(14):3660-71. doi: 10.1158/1078-0432.CCR-13-1674. Epub 2014 May 1. Clin Cancer Res. 2014. PMID: 24788102 Clinical Trial.
Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC, Neninger E, García B, Popa X, Viada C, Luaces P, González G, Lage A, Montero E, Crombet T. Rodriguez PC, et al. Among authors: viada c. J Immune Based Ther Vaccines. 2011 Oct 24;9:7. doi: 10.1186/1476-8518-9-7. J Immune Based Ther Vaccines. 2011. PMID: 22024351 Free PMC article.
30 results